Active	Status	Sponsor type	Region	Phase	Filter
6 Active 8 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Dzavik, Vladimir
SEMPATICO, NCT04615871: Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19	Recruiting	2	400	Europe, Canada, RoW	semaglutide, Ozempic	Vladimír Džavík, Unity Health Toronto, Canadian Institutes of Health Research (CIHR), University of Toronto	Covid19, Myocardial Injury	03/22	03/22
COSIRA-II, NCT05102019: Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II	Recruiting	N/A	380	Canada, US	Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry	Neovasc Inc., Shockwave Medical, Inc.	Refractory Angina	06/25	12/28
Džavík, Vladimír
SEMPATICO, NCT04615871: Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19	Recruiting	2	400	Europe, Canada, RoW	semaglutide, Ozempic	Vladimír Džavík, Unity Health Toronto, Canadian Institutes of Health Research (CIHR), University of Toronto	Covid19, Myocardial Injury	03/22	03/22
Husain, Mansoor
SEMPATICO, NCT04615871: Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19	Recruiting	2	400	Europe, Canada, RoW	semaglutide, Ozempic	Vladimír Džavík, Unity Health Toronto, Canadian Institutes of Health Research (CIHR), University of Toronto	Covid19, Myocardial Injury	03/22	03/22
NCT04759417: Comparison of CHOKAI vs STONE Score to Predict the Presence of Ureteric Stones in Patients With Renal Colic: A Multi-center Prospective Observational Study	Completed	N/A	92	RoW		Zayed Military Hospital	Ureteric Stone	03/22	07/24
Kulikova, Maria
SEMPATICO, NCT04615871: Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19	Recruiting	2	400	Europe, Canada, RoW	semaglutide, Ozempic	Vladimír Džavík, Unity Health Toronto, Canadian Institutes of Health Research (CIHR), University of Toronto	Covid19, Myocardial Injury	03/22	03/22